Findings indicate that COPD has a substantial physical and psychosocial impact on patients, particularly those aged 45–54 years old. Compared with older patients (≥65 years old), this group more frequently reported that their COPD has a higher impact on their wellbeing and daily activities, and reported making more frequent adjustments to their activity due to their symptoms.1 Survey results indicate that there are significant quality of life and educational unmet needs, particularly amongst younger people living with COPD.
“This is one of the few surveys that looks at the impact of COPD in different age groups,” said Professor Dr Dekhuijzen, Pulmonologist, Radboud University Medical Center, Nijmegen, The Netherlands. “As healthcare professionals, we have to realise that the same disease has a different impact in younger and older patients, and that the perceived impact has to be addressed to tailor and optimise treatment to suit each patient.”
When looking specifically at the outcomes reported by younger patients (45–54 years old) versus older patients (≥65 years old):
Younger patients more frequently reported that their COPD ‘extremely’ or ‘very much’ impacts their ability to carry out tasks outside the home (37% vs 22%) and travel long distances (38% vs 18%),1 and they were more than twice as likely to need to plan their day around periods of breathlessness and/or coughing (41% vs 19%)1
A significantly higher proportion of patients aged 45–54 years old reported “poor” or “very poor” wellbeing (35% vs 28%; P<0.05), and reported feeling “stressed” and “overwhelmed” 1.7 and 2.2 times more frequently (P<0.05), respectively1
Reliance on physicians was more significant amongst younger patients, who were more than three times more likely to want information to aid them to better manage using their inhaler device (18% vs 58% did not want this type of information)1
“One possible explanation as to why the perceived burden differs strongly is that younger patients are usually more active in terms of their work and social life, and so have differing expectations about what life with COPD will be,” said Nicole Hass, Representative from the European Federation of Allergy and Airways Diseases Patients’ Associations (EFA). “Although more research is needed to better understand why these age differences exist, these findings show we need to make patients more aware of how they can positively impact their disease progression through things like speaking to clinicians about optimal treatment aimed at keeping them active in their daily lives.”
Findings reinforce the need for HCPs and COPD patients, particularly younger ones, to work towards optimal treatment management and therapy aimed at improving symptoms and lessening the impact of the disease on patients’ quality of life. According to Dr. Paola Casarosa, Head of Global Therapeutic Areas at Boehringer Ingelheim, “Overall, the results of this survey align with our ongoing efforts as an organisation, highlighting the importance of optimising treatment and helping patients to maintain active lives.”
** Reposted with permission of Boehringer-Ingelheim **
An estimated 251 million people have been diagnosed with COPD, a progressive disease that limits airflow in and out of the lungs.2 There is no cure for COPD, but most patients can manage their COPD with the right medication and treatment plan.2
About the survey
This global patient survey was commissioned by Boehringer Ingelheim, and included 1,375 adults living with COPD aged 45 years and over. The online survey was fielded in 11 countries including China, Denmark, France, Germany, Italy, Japan, the Netherlands, Poland, Spain, the UK and the USA and patients were stratified by age (45–54, 55–64, ≥65 years). The objective of the survey was to assess the impact COPD has on patients’ lives.
Making new and better medicines for humans and animals is at the heart of what we do. Our mission is to create breakthrough therapies that change lives. Since its founding in 1885, Boehringer Ingelheim is independent and family-owned. We have the freedom to pursue our long-term vision, looking ahead to identify the health challenges of the future and targeting those areas of need where we can do the most good.
As a world-leading, research-driven pharmaceutical company, more than 51,000 employees create value through innovation daily for our three business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. In 2019, Boehringer Ingelheim achieved net sales of 19 billion euros. Our significant investment of almost 3.5 billion euros in R&D drives innovation, enabling the next generation of medicines that save lives and improve quality of life.
We realize more scientific opportunities by embracing the power of partnership and diversity of experts across the life-science community. By working together, we accelerate the delivery of the next medical breakthrough that will transform the lives of patients now, and in generations to come.
New study confirms the power of Deinosuchus and its ‘teeth the size of bananas’ 🐊
Revisiting fossil specimens, experts discover this huge 33ft long beast wasn't alone either!
Find out more here 👉🏽 [Read more...]
20 hours ago
Could this new #AI development lead to the discovery of new materials? 🤖
& scientists publish their findings of their machine learning approach
4 days ago
An early introduction to #mathematics and #literacy is vital for children from low income families, new research shows 📚
Preschool children who regularly read and engaged with math had enhanced vocabulary and math skills throughout school.
5 days ago
Selective reporting of antipsychotic prescriptions in US nursing homes may have misrepresented the true extent of their use, say researchers.
Prescriptions for #Tourettes, #schizophrenia and #Huntingtons were omitted from official reports.
5 days ago
Writing for , discusses research looking at nations at the forefront of developing progressive climate change legislation
Full study here 👉🏻 [Read more...]
5 days ago
More than 1 in 10 former hospital patients questioned in this study reported post #COVID19 hearing deterioration 👂🏽
Experts, including , state there's now a need to understand the effects, as well as longstanding audio-vestibular system risks
6 days ago
Would you like to read our hand-picked selection of the top, recent #COVID19 #freeaccess research? 📚
Here's our reading list featuring articles from publications and authors including
6 days ago
Was Winston Churchill's infamous 'Iron Curtain' speech misunderstood?
This article from The International History Review takes a closer look 🔎
7 days ago
Plastic from used PPE can, and should, be transformed into #renewable liquid fuels – a new #COVID19 study shows
Out today, this #recycling strategy aims to mitigate the issue of dumped PPE becoming a significant threat to the environment 🌄
7 days ago
A study looking at 4,000 children in New South Wales has found that males & females are at high risk of experiencing #sexualharassment in high school
Researchers found over 40% of both sexes reported incidents in the last school term alone